Home › Device types › MDS
Sensor, Glucose, Invasive
FDA product code MDS · Class 3 · Unknown
871
Registered devices
281,940
Adverse events
57
Recalls
0
510(k) clearances
Devices with this code
PARADIGM® REAL-time — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.G4 PLATINUM Receiver with Share Kit US — Dexcom, Inc.GUARDIAN® MiniLink® CareLink® — MEDTRONIC MINIMED, INC.PARADIGM® REAL-time — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.PARADIGM® REAL-time — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.PARADIGM® REAL-time — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.Medtronic Guardian™ Link — MEDTRONIC MINIMED, INC.ARROW — TELEFLEX INCORPORATEDPARADIGM® REAL-time — MEDTRONIC MINIMED, INC.Paradigm® REAL-Time Revel™ — MEDTRONIC MINIMED, INC.PARADIGM® REAL-time — MEDTRONIC MINIMED, INC.MiniLink® — MEDTRONIC MINIMED, INC.PARADIGM® REAL-time — MEDTRONIC MINIMED, INC.PARADIGM® REAL-time — MEDTRONIC MINIMED, INC.
Recent recalls
| Date | Firm | Reason |
|---|---|---|
| 2025-05-07 | Medtronic MiniMed, Inc. | The device cap label may not adhere to the sensor, compromising the sterility of the sensor, and increasing the risk of infection. |
| 2022-11-21 | Medtronic MiniMed | An app, part of a continuous glucose monitoring system, for use with smartphone devices may automatically log out from CareLink, then the app is not able to upl |
| 2021-02-26 | Medtronic Inc. | Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose |
| 2021-02-26 | Medtronic Inc. | Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose |
| 2021-02-26 | Medtronic Inc. | Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose |
| 2021-02-26 | Medtronic Inc. | Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose |
| 2021-02-26 | Medtronic Inc. | Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose |
| 2021-02-26 | Medtronic Inc. | Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose |
| 2021-02-26 | Medtronic Inc. | Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose |
| 2021-02-26 | Medtronic Inc. | Use of the continuous glucose monitoring system while actively taking hydroxyurea, an anti-neoplastic drug could result in inaccurate elevated sensor glucose |
Query this across every FDA database — by API.
Linked GUDID · 510(k)/PMA · MAUDE · recalls · establishments. Free tier, no card required.
Get your free API keyRead the docsSourced from public U.S. FDA data. Informational only — not medical or regulatory advice. Not affiliated with the FDA.